Tag Archives: ranolazine

Preparing for the next 25 years Opening the meeting, BSH Chair Professor Roy Gardner (University of Glasgow) spoke about the BSH‘s aim to reduce HF mortality by 25% in 25 years, which would need the bringing together of all stakeholders to improve: Prevention strategies Identifying those at risk Early accurate diagnosis Appropriate treatment In his speech, he encouraged us to be more ambitious for further progress, to raise awareness of HF, and to educate more widely to achieve further progress and benefit more patients. 25 Fellows for 25 years Table 1. The new British Society for Heart Failure Fellows John Baxter, Sunderland Lynd

PREVAIL not presented but eases safety concerns on Watchman The PREVAIL trial of a new device which closes the left atrial appendage in the heart (Watchman®, Boston Scientific) attracted huge controversy at the ACC meeting when it was removed from the programme within an hour of its presentation because of an embargo break by the sponsor, Boston Scientific. But the slides and a press release were still made available to the media, and preliminary results appear to suggest some reassurance on safety concerns generated in a previous study. The device, which is implanted via a trans-septal catheter-based delivery system, is already available in

Introduction Stable angina is the most common manifestation of coronary heart disease. While considered relatively benign in terms of prognosis, the condition confers a higher risk of cardiovascular events than in the general population, with average annual mortality rates of 1–2%. Guidelines for the management of stable angina are relatively conservative in their approach, given their process of development. Moreover, stable angina management has not been as rigorously evaluated in large randomised trials as other coronary conditions. The role of newer treatment options in management algorithms also merits wider consideration. This expert

The new guideline from the National Institute for Health and Clinical Excellence (NICE)1 covers adults who have been diagnosed with stable angina due to atherosclerotic disease, following on from clinical guideline 95,2 which advises on diagnosis of chest pain of recent onset. A key priority for implementation in the latest guidance is to ensure that people with stable angina receive balanced information and have the opportunity to discuss the benefits, limitations and risks of their treatment. Initial management of stable angina should be to offer optimal drug treatment, addressing both the angina itself and secondary prevention of cardiovas

Introduction Coronary heart disease (CHD) remains the major cause of death throughout European and other developed countries. While death rates have been consistently falling, rates in the UK remain relatively high compared to some Western European countries. The commonest clinical presentation of CHD is angina pectoris. Angina incidence rates generally increase with age and are highest in the 65−74 years age group in both men and women. The prevalence of angina is estimated to be 5% in men and 4% in women in the UK, giving a total of nearly 2.1 million (>1.2 million <75 years of age) with the condition.1 It is therefore a common dise

Recommendations Members of the Canadian Cardiovascular Society have recently issued a position statement on refractory angina (RFA).2 They have produced three recommendations: Collect accurate data on the incidence and prevalence of RFA in Canada To have a clear definition of RFA that reflects recent advancements in pain neuropathophysiology To have joint CCS and Canadian Pain Society (CPS) guidelines. The group are awaiting the results of a publicly funded study looking at the prevalence of angina six months after percutaneous coronary intervention (PCI). They are also hoping to establish a registry as part of a joint project with the CCS